Antibody Structure Prediction and Optimization
This AI-driven approach contrasts sharply with conventional methods. Unlike manual processes that depend on empirical testing, AI offers unparalleled advantages in speed, precision, innovation, and broad applicability. By analysing extensive biological data, AI accelerates design timelines and enables antibody engineering at the molecular level — optimising binding affinity and specificity with a degree of resolution that traditional approaches cannot match.
ICDMO is at the forefront of transforming antibody design and optimisation through advanced AI-driven techniques, particularly in the domain of antibody structure prediction. Leveraging current deep learning structure prediction methods, we have developed a robust platform capable of accurately predicting complex protein structures — encompassing intricate antibody–antigen interactions and monomeric protein architectures. Our specialised algorithms excel in modelling Complementarity Determining Regions (CDRs) that are critical determinants of antibody specificity and functional efficacy.
Predicting and Optimizing Antibody Structures
Our approach integrates AI methodologies to refine Fc regions and eliminate potentially deleterious Post-Translational Modification (PTM) sites, ensuring enhanced antibody stability and long-term functionality. By applying AI at every stage of structural analysis, we optimise antibody architectures to meet diverse research objectives — whether the goal is increased functional activity, extended serum circulation time, or improved batch-to-batch consistency in manufacturing performance.
Figure 1. Application of supervised learning for precise protein structure prediction.
Tailored Solutions for Enhanced Performance
1
Mutant Design and Construction
Using AI algorithms including Convolutional Neural Networks (CNN) and Long Short-Term Memory networks (LSTM), we facilitate protein design from the ground up — predicting structural changes and optimising for novel functionalities before a single experiment is run.
2
Affinity Optimisation
Employing supervised learning techniques such as Support Vector Machines (SVM) and Random Forests (RF), we enhance protein–ligand interactions and accurately predict binding affinities, which are critical determinants of therapeutic efficacy.
3
Stability Optimisation
Our deployment of Deep Neural Networks (DNN) and Recurrent Neural Networks (RNN) enables precise predictions of protein stability, accounting for complex folding pathways and dynamic structural rearrangements under physiological conditions.
4
Antibody Humanisation
AI-driven analysis predicts immunogenicity profiles and systematically optimises antibodies for compatibility with human immune systems, leveraging comprehensive datasets of human germline sequences and T-cell epitope landscapes.
5
Antibody Target Specificity Optimisation
Applying machine learning algorithms including advanced clustering and deep classification techniques, we identify relevant epitopes and sharpen antibody targeting specificity — a critical requirement for therapeutic precision and reduced off-target effects.
6
Wet Lab Validation
To verify AI-generated hypotheses, we conduct rigorous experimental assays — integrating computational predictions derived from models trained on extensive datasets with hands-on validation. This dual approach ensures the reliability and real-world applicability of every computational output.
Advantages of Our Antibody Structure Prediction and Optimization Services
Innovative Technological Edge
By harnessing the power of AI and deep learning, ICDMO accelerates antibody drug development timelines while minimising costs and risks associated with traditional empirical methods. Our AI-driven approach not only enhances prediction accuracy but also provides actionable insights into optimising the antibody characteristics most critical for therapeutic success.
Comprehensive Support
From initial sequence design through to experimental validation, our services provide fully integrated, end-to-end solutions that empower researchers to achieve breakthroughs in antibody drug development. We are committed to delivering tailored, reliable, and efficient support that addresses the unique requirements of each research programme.
Scientific Excellence
Backed by a team of experienced computational biologists and bioinformatics specialists, ICDMO ensures scientific rigour and excellence at every stage of antibody structure prediction and optimisation. Our commitment to advancing biomedicine through innovative AI technologies reflects our broader mission to shape the future of antibody-based therapeutics.
ICDMO's Antibody Structure Prediction and Optimization service represents a paradigm shift in antibody engineering, offering state-of-the-art computational tools combined with rigorous scientific expertise. Whether the objective is to enhance specificity, stability, or functional activity, our AI-driven approach is poised to redefine standards in antibody drug development — making meaningful strides toward effective treatments for cancer, autoimmune diseases, and infectious conditions.
* For research use only. Not intended for any clinical use.
Is This the Right Service for You?
Choose this when
Variable domain models are needed for design, docking or developability work
An antigen complex model would guide epitope-directed engineering
Surface liabilities must be assessed on a modelled structure
Consider another service when
Sequence engineering, not just modelling, is required
Antibody Drug Design Humanisation is the specific objective
Antibody Humanization What Goes Wrong, and How We Handle It
These are the failure modes that produce confident-looking results which do not survive the next experiment. Each one is designed against rather than discovered afterwards.
A single CDR-H3 conformation driving downstream decisions
Ensembles are delivered for uncertain loops and design decisions are tested for robustness across them.
Complex models used as though the epitope were established
Interface confidence is reported separately and, where the epitope is unknown, docking output is presented as candidate modes for mutagenesis.
Geometry problems inherited silently into design
Every model is validated for Ramachandran, rotamer and clash quality before delivery.
A Worked Example
Patch analysis on a modelled Fv
The situation
A candidate aggregated at concentration and the team had no structure.
What the work involved
The variable domains were modelled with dedicated loop treatment and validated, then surface charge and hydrophobic patches were computed and mapped onto the model.
What came back
A contiguous hydrophobic patch spanning CDR-H2 and the adjacent framework, with three substitutions proposed at non-contact positions within it and the confidence of the underlying region stated.
Illustrative of the shape this work takes. Details are generalised, no client or target is identified, and scope and outcome vary with the system in question.
What Published Work Reports
The results below were published by independent groups and are cited to show what these computational approaches have achieved in the literature. They are not ICDMO project results, and outcomes vary substantially between targets, datasets and programmes. We do not promise comparable results for any particular project.
10- to 140-fold affinity improvements from computational design
Computational interface redesign produced a tenfold affinity improvement in cetuximab, reaching 52 pM, and a 140-fold improvement to 30 pM for an anti-lysozyme model antibody — improvements achieved by designing a small number of interface substitutions rather than by library selection.
Lippow, Wittrup & Tidor, Nature Biotechnology, 2007 ↗Interface models predict which substitutions help, with measurable accuracy
A 2024 study combining structural interface analysis with sequence-derived evolutionary information reported a predictive model for antibody–antigen interaction with an area under the curve of 0.83 and precision of 0.89 on held-out data, and experimentally confirmed a designed point mutation that improved affinity 2.5-fold to 2 nM. Typical computational maturation gains are modest per mutation, which is why a designed panel is measured rather than a single variant.
Experimental validation study, 2024 ↗What We Need From You
▸Antibody sequences (VH and VL, scFv, Fab or VHH) with the numbering scheme if you use a specific one
▸Antigen sequence or structure where a complex model is required
▸Any epitope, mutagenesis or biophysical data that constrains the interaction
▸The downstream use — design, docking, developability triage or publication — since it determines preparation
▸Existing measured data such as melting temperature or aggregation behaviour, used to sanity-check predictions
How the Analysis Is Performed
▸Germline assignment, CDR definition and canonical class analysis across the framework and loops
▸Antibody-specific structure prediction with dedicated loop modelling for the hypervariable CDR-H3
▸Ensemble generation where a loop conformation is genuinely uncertain rather than forcing a single pose
▸Complex modelling with the antigen and per-interface confidence assessment
▸Geometry validation and comparison against homologous experimental structures
▸Surface and developability analysis on the modelled structure, including patch detection
What You Receive
▸Variable domain models in PDB format with per-region confidence, including CDR-H3 ensembles where the loop is uncertain
▸Antigen complex models with interface confidence reported separately from global confidence
▸Geometry validation: Ramachandran statistics, rotamer outliers, clashes and canonical class assignment
▸Surface property analysis covering charge distribution, hydrophobic patches and aggregation-prone regions
▸Prepared structures ready for docking, simulation or design work, with protonation documented
Interpretation and Limitations
Framework and most CDR loops model reliably; CDR-H3 remains the hardest loop in antibody structure prediction and is delivered as an ensemble for that reason. Antigen complex prediction is substantially less reliable than unbound modelling, particularly for novel epitopes with little structural precedent. Models support design decisions but do not replace an experimental structure where binding-mode certainty is required, and deliverables are research-use only.
Questions We Are Asked Before Scoping
How accurate is CDR-H3 prediction?
Less accurate than the other loops, and accuracy falls as the loop lengthens. We deliver an ensemble rather than a single conformation and check that any design decision holds across it.
Can you model the antibody bound to its antigen?
Yes, and the interface confidence is reported separately. Where the epitope is unknown, docking produces candidate modes rather than an answer, and we say which are worth testing by mutagenesis.
Is a model good enough for developability triage?
For surface patch and liability analysis, generally yes, since these depend on overall fold and surface composition rather than on sub-angstrom accuracy. We flag any liability that sits in a low-confidence region.
Quick Inquiry
Fill in the form below and our team will respond with a detailed proposal within one business day.